ICD-10-CM Code C77.9

Secondary and unspecified malignant neoplasm of lymph node, unspecified

Version 2021 Billable Code Neoplasm Malignant Secondary

Valid for Submission

C77.9 is a billable code used to specify a medical diagnosis of secondary and unspecified malignant neoplasm of lymph node, unspecified. The code is valid for the fiscal year 2021 for the submission of HIPAA-covered transactions. The ICD-10-CM code C77.9 might also be used to specify conditions or terms like exocrine pancreas tnm finding, exocrine pancreas tnm finding, intergroup rhabdomyosarcoma study post-surgical clinical group iic: locally extensive tumor , gross total resection, but microscopic residual disease, left regional lymph node metastasis present, m1a: non-regional lymph node metastasis, metastasis stage m1a, etc

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: Neoplasm, neoplastic lymph, lymphatic channel NEC gland (secondary) or Neoplasm, neoplastic lymph, lymphatic channel NEC gland (secondary) site NEC .

ICD-10:C77.9
Short Description:Secondary and unsp malignant neoplasm of lymph node, unsp
Long Description:Secondary and unspecified malignant neoplasm of lymph node, unspecified

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Intergroup rhabdomyosarcoma study post-surgical clinical group IIC: Locally extensive tumor , gross total resection, but microscopic residual disease
  • Left regional lymph node metastasis present
  • M1a: non-regional lymph node metastasis
  • Metastasis stage M1a
  • Metastasis to lymph node from adenocarcinoma
  • Metastasis to lymph node from squamous cell carcinoma
  • Metastasis to lymph node of unknown primary
  • Metastatic squamous cell carcinoma
  • N1 category
  • N1: Metastasis in 1-3 lymph nodes
  • N1: Metastasis in a single ipsilateral lymph node, < 3 cm in greatest dimension
  • N1: Metastasis in a single lymph node
  • N1: Metastasis in a single lymph node, < 2 cm in greatest dimension
  • N1: Metastasis in a single lymph node, <= 2 cm in greatest dimension
  • N1: Metastasis in regional lymph node or nodes
  • N1: Metastasis with a lymph node mass less than 2 cm in greatest dimension and 5 or fewer positive nodes, none larger than 2 cm in greatest dimension
  • N1: Pelvic or inguinal lymph node metastasis
  • N1: Regional lymph node metastasis
  • N1a: 1-3 nodes involved
  • N1a: Metastasis in single regional lymph node
  • N1a: Only micrometastasis, none > 0.2 cm in greatest dimension
  • N1b: 4-7 nodes involved
  • N1b: Metastasis to lymph node, any > 0.2 cm in greatest dimension
  • N1bi: Metastasis in 1 to 3 lymph nodes, any > 0.2 cm and all < 2 cm in greatest dimension
  • N1bii: Metastasis in 4 or more lymph nodes, any > 0.2 cm and all < 2 cm in greatest dimension
  • N1biii: Extension of tumor beyond the capsule of a lymph node metastasis, < 2 cm in greatest dimension
  • N1biv: Metastasis to a lymph node > 2 cm in greatest dimension
  • N1c: >7 nodes involved
  • N2 category
  • N2: Metastasis in 4 or more lymph nodes
  • N2: Metastasis in a single ipsilat lymph node >3cm but <6cm in greatest dimension; or in multiple ipsilat lymph nodes, none >6cm in greatest dimension; or in bilat or contralat lymph nodes, none >6cm in greatest dimension
  • N2: Metastasis in a single lymph node, > 2 cm but <= 5 cm in greatest dimension, or multiple lymph nodes, none > 5 cm in greatest dimension
  • N2: Metastasis in more than one regional lymph node
  • N2: Metastasis with a lymph node mass >2 cm but <= 5 cm in greatest dimension, or more than 5 nodes positive, none > 5 cm; or evidence of extranodal extension of tumor
  • N2a: Metastasis in a single ipsilateral lymph node, > 3 cm but < 6 cm in greatest dimension
  • N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension
  • N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension
  • N3 category
  • N3: Metastasis in a lymph node > 5 cm in greatest dimension
  • N3: Metastasis in a lymph node > 6 cm in greatest dimension
  • N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node
  • N3: Metastasis in lymph node
  • N3: Metastasis with a lymph node mass > 5 cm in greatest dimension
  • N3a: > 6 cm in dimension
  • N4 category
  • Node stage N1a
  • Node stage N1b
  • Node stage N1bi
  • Node stage N1bii
  • Node stage N1biii
  • Node stage N1biv
  • Node stage N2a
  • Node stage N2b
  • Node stage N2c
  • pM1a: Distant metastasis to non-regional lymph node
  • pM1a: Metastasis to skin, subcutaneous tissues, or distant lymph nodes
  • pM1b: Distant metastasis
  • pM1b: Nonregional lymph nodes AND/OR other distant metastasis
  • pN1
  • pN1
  • pN1
  • pN1
  • pN1
  • pN1
  • pN1 category
  • pN1: Metastasis in 1 to 3 axillary lymph nodes, and/or in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
  • pN1: Metastasis in 1 to 3 regional lymph nodes
  • pN1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
  • pN1: Metastasis in a single lymph node, 2 cm or less in greatest dimension
  • pN1: Metastasis in a single regional lymph node
  • pN1: Metastasis in one regional lymph node
  • pN1: Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension
  • pN1: Pelvic or inguinal lymph node metastasis
  • pN1: Unilateral regional lymph node metastasis
  • pN1a category
  • pN1a: Clinically occult
  • pN1a: Metastasis in 1 to 3 regional lymph nodes
  • pN1a: Metastasis in single regional lymph node
  • pN1b category
  • pN1b: Clinically apparent
  • pN1b: Metastasis in 4 to 7 regional lymph nodes
  • pN1b: Metastasis in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
  • pN1b: Metastasis in multiple regional lymph node
  • pN1b: Metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph nodes
  • pN1c category
  • pN1c: Metastasis in more than 7 regional lymph nodes
  • pN1mi
  • pN1mi category
  • pN1mi: Micrometastasis
  • pN2 category
  • pN2: Metastasis in 2 to 3 regional nodes or intralymphatic regional metastasis without nodal metastasis
  • pN2: Metastasis in 4 or more regional lymph nodes
  • pN2: Metastasis in 4 to 9 axillary lymph nodes, or in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis
  • pN2: Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension
  • pN2: Metastasis in more than one regional lymph node
  • pN2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor
  • pN2a category
  • pN2a: Clinically occult
  • pN2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
  • pN2b category
  • pN2b: Clinically apparent
  • pN2b: Metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis
  • pN2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
  • pN2c category
  • pN2c: Satellite or in-transit metastasis without nodal metastasis
  • pN3 category
  • pN3: Metastasis in a lymph node
  • pN3: Metastasis in a lymph node, more than 5 cm in greatest dimension
  • pN3: Metastasis in a lymph node, more than 6 cm in greatest dimension
  • pN3: Metastasis in four or more regional nodes, or matted metastatic nodes, or in-transit metastasis or satellite
  • pN3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes
  • pN3: Metastasis with a lymph node mass more than 5 cm in greatest dimension
  • pN3a category
  • pN3a: Metastasis in a lymph node
  • pN3b category
  • pN3b: Tumor of breast with metastasis as per AJCC 6th Edition definition
  • pN3c category
  • pN4 category
  • pT3 and/or N1
  • pT3 and/or N1
  • pT3c AND/OR N1
  • pT3c and/or N1
  • Regional lymph node metastasis present
  • Right regional lymph node metastasis present
  • Secondary malignant neoplasm of lymph node
  • Secondary malignant neoplasm of lymph node from neoplasm of female breast
  • T3 and/or N1 with peritoneal implants outside the pelvis and/or regional lymph node metastasis
  • Thyroid TNM finding
  • Tumor metastasis to non-regional lymph nodes present
  • Vagina TNM finding

Diagnostic Related Groups

The ICD-10 code C77.9 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2021.

  • 820 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC
  • 821 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC
  • 822 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC

Convert C77.9 to ICD-9

  • 196.9 - Mal neo lymph node NOS

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-C80)
      • Secondary and unspecified malignant neoplasm of lymph nodes (C77)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Table of Neoplasms

The code C77.9 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»Neoplasm, neoplastic
  »lymph, lymphatic channel NEC
    »gland (secondary)
C77.9D36.0D48.7D49.89
»Neoplasm, neoplastic
  »lymph, lymphatic channel NEC
    »gland (secondary)
      »site NEC
C77.9D36.0D48.7D49.89

Information for Patients


Cancer

Also called: Carcinoma, Malignancy, Neoplasms, Tumor

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

  • Cancer (Medical Encyclopedia)
  • Cancer and lymph nodes (Medical Encyclopedia)
  • Cancer treatment -- early menopause (Medical Encyclopedia)
  • Cancer treatment: preventing infection (Medical Encyclopedia)
  • Cancer treatments (Medical Encyclopedia)
  • How to research cancer (Medical Encyclopedia)
  • How to tell your child that you have cancer (Medical Encyclopedia)
  • Hyperthermia for treating cancer (Medical Encyclopedia)
  • Laser therapy for cancer (Medical Encyclopedia)
  • Photodynamic therapy for cancer (Medical Encyclopedia)
  • Targeted therapies for cancer (Medical Encyclopedia)
  • Understanding your cancer prognosis (Medical Encyclopedia)
  • Your cancer care team (Medical Encyclopedia)
  • Your cancer diagnosis: Do you need a second opinion? (Medical Encyclopedia)

[Learn More]